Number of persons employed by the Entity

No definition available.

Name:	dei_EntityNumberOfEmployees
Namespace Prefix:	dei_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	instant

- Definition

Asset Purchase Agreement, Royalty On Net Profits of Products, Term

+ References

No definition available.

+ Details

Name:	egrx_AssetPurchaseAgreementRoyaltyOnNetProfitsofProductsTerm
Namespace Prefix:	egrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Business Combination, Consideration Transferred, Including Contingent Consideration Arrangements, Range of Outcomes, High

+ References

No definition available.

+ Details

Name:	egrx_BusinessCombinationConsiderationTransferredIncludingContingentConsiderationArrangementsRangeofOutcomesHigh
Namespace Prefix:	egrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Business Combination, Contingent Consideration, Liability, Percentage of Gross Profits

+ References

No definition available.

+ Details

Name:	egrx_BusinessCombinationContingentConsiderationLiabilityPercentageofGrossProfits
Namespace Prefix:	egrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Exclusive Rights, Term

+ References

No definition available.

+ Details

Name:	egrx_ExclusiveRightsTerm
Namespace Prefix:	egrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License Agreements, Milestone Payment Benchmark, Net Sales

+ References

No definition available.

+ Details

Name:	egrx_LicenseAgreementsMilestonePaymentBenchmarkNetSales
Namespace Prefix:	egrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Licensing Agreement, Proceeds From Unique Billing Code

+ References

No definition available.

+ Details

Name:	egrx_LicensingAgreementProceedsFromUniqueBillingCode
Namespace Prefix:	egrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum Expected Cash Proceeds On Additional Milestones

+ References

No definition available.

+ Details

Name:	egrx_MaximumExpectedCashProceedsOnAdditionalMilestones
Namespace Prefix:	egrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number Of Products

+ References

No definition available.

+ Details

Name:	egrx_NumberOfProducts
Namespace Prefix:	egrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Proceeds Receivable Upon Each Regulatory Approval

+ References

No definition available.

+ Details

Name:	egrx_ProceedsReceivableUponEachRegulatoryApproval
Namespace Prefix:	egrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Proceeds Receivable Upon Regulatory Approvals, Maximum

+ References

No definition available.

+ Details

Name:	egrx_ProceedsReceivableUponRegulatoryApprovalsMaximum
Namespace Prefix:	egrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Proceeds from Agreement to Reduce Royalty Revenue Percentage

+ References

No definition available.

+ Details

Name:	egrx_ProceedsfromAgreementtoReduceRoyaltyRevenuePercentage
Namespace Prefix:	egrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Related Party, Cost Sharing, Percentage

+ References

No definition available.

+ Details

Name:	egrx_RelatedPartyCostSharingPercentage
Namespace Prefix:	egrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Related Party, Number of Employees

+ References

No definition available.

+ Details

Name:	egrx_RelatedPartyNumberofEmployees
Namespace Prefix:	egrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Related Party, Percentage of Time Allocated

+ References

No definition available.

+ Details

Name:	egrx_RelatedPartyPercentageofTimeAllocated
Namespace Prefix:	egrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Related Party, Service Period, Extension Option

+ References

No definition available.

+ Details

Name:	egrx_RelatedPartyServicePeriodExtensionOption
Namespace Prefix:	egrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Revenue, Percentage of Gross Profits

+ References

No definition available.

+ Details

Name:	egrx_RoyaltyRevenuePercentageofGrossProfits
Namespace Prefix:	egrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Revenue, Percentage of Net Sales

+ References

No definition available.

+ Details

Name:	egrx_RoyaltyRevenuePercentageofNetSales
Namespace Prefix:	egrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of shares of equity interests issued or issuable to acquire entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Percentage points added to the reference rate to compute the variable rate on the debt instrument.

+ References

No definition available.

+ Details

Name:	us-gaap_DebtInstrumentBasisSpreadOnVariableRate1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_DebtInstrumentTerm
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.

+ References

No definition available.

+ Details

Name:	us-gaap_LineOfCreditFacilityCommitmentFeePercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a),(d))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_OtherSalesRevenueNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received from licensees for license fees during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name:	us-gaap_ProceedsFromSaleOfProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of stock repurchase plan authorized.

+ References

No definition available.

+ Details

Name:	us-gaap_StockRepurchaseProgramAuthorizedAmount1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsidiarySaleOfStockLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of shares that have been repurchased during the period and are being held in treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name:	us-gaap_TreasuryStockSharesAcquired
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name:	us-gaap_TreasuryStockValueAcquiredCostMethod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_MajorCustomersAxis=egrx_CephalonInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=egrx_AlbanyMolecularResearchInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=egrx_JointlyDevelopandManufactureDrugProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AffiliatedEntityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=egrx_TevaPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=egrx_SpectrumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=egrx_SpectrumAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=egrx_AlbanyMolecularResearchInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=egrx_BendekaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=egrx_CephalonInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=egrx_RyanodexMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=egrx_RoyaltyBuyBackAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=egrx_NonAlcoholDocetaxelInjectionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=egrx_EagleBiologicsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=egrx_RoyaltiesonGrossProfitsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=egrx_MilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VariableRateAxis=us-gaap_PrimeRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Organization and Business Activities (Details)													1 Months Ended					2 Months Ended	3 Months Ended					12 Months Ended
Organization and Business Activities (Details)	Jan. 26, 2017 USD ($)	Nov. 16, 2016 USD ($) shares	Nov. 02, 2016	Aug. 03, 2016 USD ($)	Aug. 02, 2016	Mar. 29, 2016	Mar. 28, 2016	Jan. 12, 2016 USD ($)	Jan. 11, 2016	Nov. 04, 2015 person	Oct. 13, 2015 USD ($)	Feb. 13, 2015 USD ($)	Mar. 31, 2017 USD ($) product	Dec. 31, 2016 USD ($)	Nov. 30, 2016 USD ($)	Jan. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2016	Mar. 31, 2017 USD ($) product shares	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2016 USD ($) shares	Aug. 09, 2016 USD ($)
Subsidiary, Sale of Stock [Line Items]
Number of products \| product													5						5
Payments to acquire business																			$ 0			$ 4,850,000
Proceeds from sale of diclofenac-misoprostol																			$ 0			1,750,000
Stock repurchase program, authorized amount																									$ 75,000,000.0
Shares of common stock repurchased (in shares) \| shares																			189,145					566,838
Value of common stock repurchased																			$ 13,653,000					$ 37,000,000
License and other revenue																			25,000,000			6,000,000
Cephalon, Inc.
Subsidiary, Sale of Stock [Line Items]
Proceeds from milestone payment												$ 30,000,000	$ 25,000,000			$ 30,000,000	$ 15,000,000						$ 30,000,000
Licensing agreement, proceeds from unique billing code														$ 40,000,000	$ 40,000,000					$ 40,000,000
Maximum additional milestone payments (up to)																			25,000,000
Royalty revenue, percentage of net sales												20.00%
Diclofenac-misoprostol
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of diclofenac-misoprostol																						$ 1,750,000
Royalty revenue, percentage of gross profits						25.00%
Royalty revenue term						5 years
AMRI \| Jointly Develop and Manufacture Drug Products \| Affiliated Entity
Subsidiary, Sale of Stock [Line Items]
Cost sharing percentage									62.50%
Teva Pharmaceuticals \| Cephalon, Inc.
Subsidiary, Sale of Stock [Line Items]
Milestone payment benchmark, net sales																			$ 500,000,000					$ 500,000,000
Spectrum \| Spectrum Agreement \| Affiliated Entity
Subsidiary, Sale of Stock [Line Items]
Percentage of time allocated										80.00%
Number of employees on the Corporate Accounts Sales Team \| person										32
Extension term										6 months
Number of employees \| person										50
AMRI \| Jointly Develop and Manufacture Drug Products \| Affiliated Entity
Subsidiary, Sale of Stock [Line Items]
Cost sharing percentage									37.50%
Bendeka
Subsidiary, Sale of Stock [Line Items]
Exclusive rights, term							7 years
Bendeka \| Cephalon, Inc.
Subsidiary, Sale of Stock [Line Items]
License and other revenue																					$ 1,750,000
Proceeds receivable upon each regulatory approval																					750,000
Maximum proceeds receivable upon regulatory approvals (up to)																					$ 2,250,000.00
Ryanodex
Subsidiary, Sale of Stock [Line Items]
Royalty revenue, percentage of net sales				3.00%	15.00%
Ryanodex \| Ryanodex intangible
Subsidiary, Sale of Stock [Line Items]
Proceeds from agreement to reduce royalty revenue percentage				$ 15,000,000
Non-Alcohol Docetaxel Injection \| Docetaxel product rights
Subsidiary, Sale of Stock [Line Items]
Payments to acquire business								$ 4,850,000			$ 250,000
Eagle Biologics
Subsidiary, Sale of Stock [Line Items]
Payments to acquire business		$ 27,209,000
Business combination equity consideration (in shares) \| shares		40,200
Business combination equity consideration		$ 3,046,000
Royalties on Gross Profits \| Non-Alcohol Docetaxel Injection \| Docetaxel product rights
Subsidiary, Sale of Stock [Line Items]
Contingent consideration, percentage of gross profits								25.00%								25.00%
Milestone Payments \| Eagle Biologics
Subsidiary, Sale of Stock [Line Items]
Business combination, contingent consideration range of outcome high		48,000,000
Business combination consideration including contingent consideration		$ 78,000,000
Minimum \| Cephalon, Inc.
Subsidiary, Sale of Stock [Line Items]
Royalty revenue, percentage of net sales			20.00%									20.00%		20.00%
Maximum \| Cephalon, Inc.
Subsidiary, Sale of Stock [Line Items]
Royalty revenue, percentage of net sales														25.00%	25.00%			25.00%
Revolving Credit Facility \| Line of Credit
Subsidiary, Sale of Stock [Line Items]
Debt instrument, term	3 years
Maximum borrowing capacity	$ 50,000,000
Revolving Credit Facility \| Line of Credit \| Minimum
Subsidiary, Sale of Stock [Line Items]
Line of credit facility, commitment fee percentage	0.35%
Revolving Credit Facility \| Line of Credit \| Maximum
Subsidiary, Sale of Stock [Line Items]
Line of credit facility, commitment fee percentage	0.40%
Letter of Credit \| Line of Credit
Subsidiary, Sale of Stock [Line Items]
Maximum borrowing capacity	$ 5,000,000
London Interbank Offered Rate (LIBOR) \| Revolving Credit Facility \| Line of Credit \| Minimum
Subsidiary, Sale of Stock [Line Items]
Variable interest rate spread	2.50%
London Interbank Offered Rate (LIBOR) \| Revolving Credit Facility \| Line of Credit \| Maximum
Subsidiary, Sale of Stock [Line Items]
Variable interest rate spread	3.00%
Prime Rate \| Revolving Credit Facility \| Line of Credit \| Minimum
Subsidiary, Sale of Stock [Line Items]
Variable interest rate spread	1.50%
Prime Rate \| Revolving Credit Facility \| Line of Credit \| Maximum
Subsidiary, Sale of Stock [Line Items]
Variable interest rate spread	2.00%